Novo Nordisk Invests DKK1.5 Billion in New Manufacturing Facility in Denmark
04 May 2015 - 4:39PM
Dow Jones News
By Dominic Chopping
Novo Nordisk A/S (NOV) said Monday it is investing DKK1.5
billion in new haemophilia treatment manufacturing facility in
Denmark.
The Danish pharmaceutical company said the new facility in
Kalundborg, Denmark will produce active pharmaceutical ingredients
for its NovoSeven product as well as future products for treating
haemophilia.
The investment is estimated to create 100 new production and
engineering jobs in Kalundborg, where Novo Nordisk currently
employs more than 2,800 people, it said.
The facility is expected to be approved and fully operational in
2020.
-Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter:
@WSJNordics
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2024 to May 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From May 2023 to May 2024